Anti-Interleukin-6 (IL6) in Calciphylaxis

Inclusion Criteria: * Must have a clinical diagnosis of calciphylaxis (calcific uremic arteriolopathy) as determined by a board-certified dermatologist or surgeon. * Diagnosis must be supported by either: * Histopathology: A skin biopsy showing characteristic medial arteriolar calcification, subintimal fibrosis, or microvascular thrombosis. * Clinical Presentation: In cases where a biopsy is clinically contraindicated, the presence of characteristic ischemic or necrotic skin lesions in a distribution typical for calciphylaxis (e.g., adipose-rich areas like the abdomen, thighs, or buttocks). * Must have advanced kidney disease, defined as: * End-Stage Kidney Disease (ESKD): Requiring maintenance hemodialysis or peritoneal dialysis. * Chronic Kidney Disease (CKD): Stage 4 or 5 \[estimated Glomerular Filtration Rate (eGFR) \< 30 mL/min/1.73m²\]. * Participants must be able to understand and provide written informed consent. in accordance with local institutional and regulatory guidelines. * Subjects of childbearing potential must agree to use highly effective contraception for the duration of the study and for at least 3 months following the final dose of Tocilizumab. * Must be willing to undergo blood draws for systemic biomarker analysis (CRP, sTF) as outlined in the study schedule, and safety monitoring. Exclusion Criteria: * Presence of any active, clinically significant infection (bacterial, viral, fungal, or opportunistic) that, in the opinion of the investiga…